Details for New Drug Application (NDA): 218096
✉ Email this page to a colleague
The generic ingredient in TOFACITINIB CITRATE is tofacitinib citrate. There are twelve drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.
Summary for 218096
| Tradename: | TOFACITINIB CITRATE |
| Applicant: | Apotex |
| Ingredient: | tofacitinib citrate |
| Patents: | 0 |
Pharmacology for NDA: 218096
| Mechanism of Action | Janus Kinase Inhibitors |
Suppliers and Packaging for NDA: 218096
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TOFACITINIB CITRATE | tofacitinib citrate | TABLET;ORAL | 218096 | ANDA | Apotex Corp. | 60505-6263 | 60505-6263-5 | 500 TABLET, FILM COATED in 1 BOTTLE (60505-6263-5) |
| TOFACITINIB CITRATE | tofacitinib citrate | TABLET;ORAL | 218096 | ANDA | Apotex Corp. | 60505-6263 | 60505-6263-6 | 60 TABLET, FILM COATED in 1 BOTTLE (60505-6263-6) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE | ||||
| Approval Date: | Jun 3, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | Jun 3, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
